23.94MMarket Cap
LossP/E TTM
Key Figures
2.160Open
2.250High
73.17KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.68%Turnover Ratio
2.150Prev. Close
2.130Low
126.90KTurnover
LossP/E Static
0.68P/B
0.00%Div Yield TTM
-28.93%ROA
3.06552wk High
2.75Volume Ratio
-13.56MNet Profit
10.73MShares
-4.6080EPS TTM
0.25Beta
-97.42%ROE
1.46052wk Low
5.58%Amplitude
55.10%Gross Margin
23.94MMarket Cap
-0.14Reward/Risk
3.30%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Aytu Biopharma Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 81 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aytu Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Aytu Biopharma Inc Highlights
StrengthsRisks
Aytu Biopharma Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aytu Biopharma Inc Info
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Ticker SymbolAYTU
CompanyAytu Biopharma Inc
CEODisbrow (Joshua R)
Websitehttps://aytubio.com/
Shareholders
FAQs
What is the current price of Aytu Biopharma Inc (AYTU)?
The current price of Aytu Biopharma Inc (AYTU) is 2.24.
What is the symbol of Aytu Biopharma Inc?
The ticker symbol of Aytu Biopharma Inc is AYTU.
What is the 52-week high of Aytu Biopharma Inc?
The 52-week high of Aytu Biopharma Inc is 3.06.
What is the 52-week low of Aytu Biopharma Inc?
The 52-week low of Aytu Biopharma Inc is 1.46.
What is the market capitalization of Aytu Biopharma Inc?
The market capitalization of Aytu Biopharma Inc is 24.04M.
Is Aytu Biopharma Inc (AYTU) currently rated as Buy, Hold, or Sell?
According to analysts, Aytu Biopharma Inc (AYTU) has an overall rating of Buy, with a price target of 9.50.
What is the Earnings Per Share (EPS TTM) of Aytu Biopharma Inc (AYTU)?
The Earnings Per Share (EPS TTM) of Aytu Biopharma Inc (AYTU) is -2.16.
